Evidence map›Paper›PMID 30112000›Full record

ArticleJournal of oncology2018

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.

Robert F H Walter, Robert Werner, Michael Wessolly, Elena Mairinger, Sabrina Borchert, Jan Schmeller, Jens Kollmeier, Thomas Mairinger, Thomas Hager, Agnes Bankfalvi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Senescence under appraisal: hopes and challenges revisited.Cellular and molecular life sciences : CMLS · 2021
    Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Robert F H WalterInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Robert WernerDepartment of Pathology, Helios Klinikum Emil von Behring, Berlin, Germany.
Michael WessollyInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0002-4399-8646
Elena MairingerInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Sabrina BorchertInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0002-0447-3206
Jan SchmellerInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0002-2012-2350
Jens KollmeierDepartment of Pneumology, Helios Klinikum Emil von Behring, Berlin, Germany.
Thomas MairingerDepartment of Pathology, Helios Klinikum Emil von Behring, Berlin, Germany.
Thomas HagerInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Agnes BankfalviInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Daniel C ChristophDepartment of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Wilfried E E EberhardtRuhrlandklinik, West German Lung Center, University Hospital Essen, University of Duisburg-Essen, Germany.
Till PlönesDepartment of Thoracic Surgery and Thoracic Endoscopy, Ruhrlandklinik, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Clemens AignerDepartment of Thoracic Surgery and Thoracic Endoscopy, Ruhrlandklinik, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Kurt W SchmidInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Jeremias WohlschlaegerInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Fabian D MairingerInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0003-1067-0051

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously, our group demonstrated that nuclear expression of E3 ubiquitin ligase (MDM2) in malignant pleural mesothelioma (MPM) is significantly associated with decreased overall survival. A possible explanation may be that overexpression of MDM2 leads to a proteasomal degradation of TP53 that eventually results in a loss of TP53-induced apoptosis and senescence. It is well known from other tumor entities that restoration of TP53 activity, e.g., by MDM2 inhibition, results in an instant TP53-induced stress and/or DNA damage response of cancer cells. Nutlin-3A (a

Identifiers

PMID30112000
PMCPMC6077509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.